Alnylam Pharmaceuticals (ALNY) Receivables (2009 - 2026)

Alnylam Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $884.0 million for Q1 2026.

• Quarterly Receivables rose 111.46% year-over-year to $884.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $884.0 million (up 111.46% YoY) and the FY2025 annual result came in at $777.6 million, up 91.85% from the prior year.
• Receivables was $884.0 million for Q1 2026 at Alnylam Pharmaceuticals, up from $777.6 million in the prior quarter.
• Across five years, Receivables topped out at $964.8 million in Q3 2025 and bottomed at $9.1 million in Q2 2022.
• A 5-year average of $379.7 million and a median of $321.4 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables sank 98.3% — and 2023, when it jumped 2331.51%.
• Alnylam Pharmaceuticals' Receivables stood at $238.0 million in 2022, then slumped by 58.15% to $99.6 million in 2023, then surged by 307.03% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025, then climbed by 13.68% to $884.0 million in 2026.
• Business Quant data shows ALNY's Receivables at $884.0 million in Q1 2026, $777.6 million in Q4 2025, and $964.8 million in Q3 2025.